VEGFR2/CD309 antibody
Quick Overview for VEGFR2/CD309 antibody (ABIN5646980)
Target
See all VEGFR2/CD309 (VEGFR2) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Purification
- Antigen affinity purified
-
Immunogen
- A recombinant human protein corresponding to amino acids A20-L242 was used as the immunogen for the VEGFR2 antibody.
-
Isotype
- IgG
-
-
-
-
Application Notes
- Optimal dilution of the VEGFR2 antibody should be determined by the researcher.\. Western Blot: 0.5-1 μg/mL,IHC (FFPE): 1-2 μg/mL,ELISA (Capture, recombinant human protein): 0.1-0.5 μg/mL (BSA-free format available)
-
Restrictions
- For Research Use only
-
-
-
Buffer
- 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water
-
Storage
- -20 °C
-
Storage Comment
- After reconstitution, the VEGFR2 antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.
-
-
- VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))
-
Alternative Name
- VEGF Receptor 2 / VEGFR2 / KDR
-
Background
- KDR (Kinase Insert Domain Receptor), also known as FLK1, VEGFR or VEGFR2, is a VEGF receptor. KDR is the human gene encoding it. Vascular endothelial growth factor (VEGF) is the only mitogen that specifically acts on endothelial cells. Its expression is upregulated by hypoxia, and its cell-surface receptor, known as fetal liver kinase-1 (Flk1) in mouse, is exclusively expressed in endothelial cells. Flk1 is the mouse homolog of KDR.
-
UniProt
- P35968
-
Pathways
- RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling
Target
-